if you change the solubility of the drug ("RC 110 tends to precipitate in peripheral veins"), you have potentially changed the performance, and therefore due diligence would warrant confirmation of no change to performance.
My point about CVC Vs PIVC is about infection, and the advantages in the latter, and in no way related to metabolism.
Being able to administer peripherally is easier and less risky. The fact that bisantrene can be administered via this route route means that is also less irritant from a phlebitis point of view which is a big problem for most chemotherapeutics and a point of difference.
As i said, this is a very attractive feature and i still remain confident of outsized returns
- Forums
- ASX - By Stock
- RAC
- Ann: H1 2023 Preclinical and Clinical Programs Update
Ann: H1 2023 Preclinical and Clinical Programs Update, page-55
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.70 |
Change
0.050(3.03%) |
Mkt cap ! $289.6M |
Open | High | Low | Value | Volume |
$1.66 | $1.70 | $1.63 | $181.9K | 109.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 11946 | $1.70 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.75 | 27579 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6605 | 1.635 |
1 | 10752 | 1.615 |
2 | 20016 | 1.610 |
2 | 21000 | 1.600 |
1 | 1279 | 1.555 |
Price($) | Vol. | No. |
---|---|---|
1.750 | 14579 | 3 |
1.755 | 990 | 1 |
1.760 | 500 | 1 |
1.800 | 824 | 2 |
1.820 | 4000 | 3 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online